Logo image of FOLD

AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis

NASDAQ:FOLD - Nasdaq - US03152W1099 - Common Stock - Currency: USD

6.67  -0.01 (-0.15%)

After market: 6.67 0 (0%)

Fundamental Rating

4

Taking everything into account, FOLD scores 4 out of 10 in our fundamental rating. FOLD was compared to 563 industry peers in the Biotechnology industry. There are concerns on the financial health of FOLD while its profitability can be described as average. FOLD shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year FOLD has reported negative net income.
In the past year FOLD has reported a negative cash flow from operations.
In the past 5 years FOLD always reported negative net income.
In the past 5 years FOLD always reported negative operating cash flow.
FOLD Yearly Net Income VS EBIT VS OCF VS FCFFOLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -7.15%, FOLD belongs to the top of the industry, outperforming 87.48% of the companies in the same industry.
The Return On Equity of FOLD (-28.91%) is better than 78.84% of its industry peers.
The Return On Invested Capital of FOLD (4.23%) is better than 93.47% of its industry peers.
Industry RankSector Rank
ROA -7.15%
ROE -28.91%
ROIC 4.23%
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
FOLD Yearly ROA, ROE, ROICFOLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

FOLD's Operating Margin of 6.45% is amongst the best of the industry. FOLD outperforms 93.47% of its industry peers.
FOLD has a better Gross Margin (89.98%) than 91.36% of its industry peers.
In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.
Industry RankSector Rank
OM 6.45%
PM (TTM) N/A
GM 89.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
FOLD Yearly Profit, Operating, Gross MarginsFOLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), FOLD is destroying value.
Compared to 1 year ago, FOLD has more shares outstanding
Compared to 5 years ago, FOLD has more shares outstanding
The debt/assets ratio for FOLD has been reduced compared to a year ago.
FOLD Yearly Shares OutstandingFOLD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
FOLD Yearly Total Debt VS Total AssetsFOLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

FOLD has an Altman-Z score of -1.44. This is a bad value and indicates that FOLD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of FOLD (-1.44) is comparable to the rest of the industry.
A Debt/Equity ratio of 2.01 is on the high side and indicates that FOLD has dependencies on debt financing.
FOLD has a Debt to Equity ratio of 2.01. This is amonst the worse of the industry: FOLD underperforms 81.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.01
Debt/FCF N/A
Altman-Z -1.44
ROIC/WACC0.38
WACC11.12%
FOLD Yearly LT Debt VS Equity VS FCFFOLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

FOLD has a Current Ratio of 3.39. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.39, FOLD is not doing good in the industry: 60.67% of the companies in the same industry are doing better.
FOLD has a Quick Ratio of 2.60. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
FOLD has a worse Quick ratio (2.60) than 68.25% of its industry peers.
Industry RankSector Rank
Current Ratio 3.39
Quick Ratio 2.6
FOLD Yearly Current Assets VS Current LiabilitesFOLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.71% over the past year.
The Revenue has grown by 32.28% in the past year. This is a very strong growth!
FOLD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.73% yearly.
EPS 1Y (TTM)64.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%145.45%
Revenue 1Y (TTM)32.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%30.09%

3.2 Future

The Earnings Per Share is expected to grow by 77.43% on average over the next years. This is a very strong growth
Based on estimates for the next years, FOLD will show a very strong growth in Revenue. The Revenue will grow by 20.68% on average per year.
EPS Next Y118.26%
EPS Next 2Y95.6%
EPS Next 3Y83.76%
EPS Next 5Y77.43%
Revenue Next Year19.78%
Revenue Next 2Y20.98%
Revenue Next 3Y21.3%
Revenue Next 5Y20.68%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
FOLD Yearly Revenue VS EstimatesFOLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
FOLD Yearly EPS VS EstimatesFOLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 3

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 202.96, FOLD can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, FOLD is valued cheaper than 89.59% of the companies in the same industry.
FOLD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.81.
Industry RankSector Rank
PE N/A
Fwd PE 202.96
FOLD Price Earnings VS Forward Price EarningsFOLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200

4.2 Price Multiples

92.77% of the companies in the same industry are more expensive than FOLD, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 50.64
FOLD Per share dataFOLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
FOLD's earnings are expected to grow with 83.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y95.6%
EPS Next 3Y83.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FOLD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMICUS THERAPEUTICS INC

NASDAQ:FOLD (5/2/2025, 8:00:01 PM)

After market: 6.67 0 (0%)

6.67

-0.01 (-0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/bmo
Earnings (Next)05-21 2025-05-21/bmo
Inst Owners94.04%
Inst Owner Change0.01%
Ins Owners0.7%
Ins Owner Change12.82%
Market Cap2.05B
Analysts82.22
Price Target17.03 (155.32%)
Short Float %6.47%
Short Ratio5.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.84%
Min Revenue beat(2)-0.84%
Max Revenue beat(2)2.52%
Revenue beat(4)2
Avg Revenue beat(4)0.36%
Min Revenue beat(4)-2.65%
Max Revenue beat(4)2.52%
Revenue beat(8)5
Avg Revenue beat(8)0.64%
Revenue beat(12)7
Avg Revenue beat(12)-0.63%
Revenue beat(16)8
Avg Revenue beat(16)-1.2%
PT rev (1m)-0.6%
PT rev (3m)-2.29%
EPS NQ rev (1m)-2.08%
EPS NQ rev (3m)-444.4%
EPS NY rev (1m)11.53%
EPS NY rev (3m)-75.63%
Revenue NQ rev (1m)-0.56%
Revenue NQ rev (3m)-3.46%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-1.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 202.96
P/S 3.89
P/FCF N/A
P/OCF N/A
P/B 10.58
P/tB N/A
EV/EBITDA 50.64
EPS(TTM)-0.18
EYN/A
EPS(NY)0.03
Fwd EY0.49%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS1.72
BVpS0.63
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.15%
ROE -28.91%
ROCE 5.35%
ROIC 4.23%
ROICexc 6.96%
ROICexgc 15.7%
OM 6.45%
PM (TTM) N/A
GM 89.98%
FCFM N/A
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score5
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 2.01
Debt/FCF N/A
Debt/EBITDA 9.16
Cap/Depr 41.57%
Cap/Sales 0.67%
Interest Coverage 0.58
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.39
Quick Ratio 2.6
Altman-Z -1.44
F-Score5
WACC11.12%
ROIC/WACC0.38
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%145.45%
EPS Next Y118.26%
EPS Next 2Y95.6%
EPS Next 3Y83.76%
EPS Next 5Y77.43%
Revenue 1Y (TTM)32.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%30.09%
Revenue Next Year19.78%
Revenue Next 2Y20.98%
Revenue Next 3Y21.3%
Revenue Next 5Y20.68%
EBIT growth 1Y144.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year195.67%
EBIT Next 3Y119.1%
EBIT Next 5YN/A
FCF growth 1Y51.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.95%
OCF growth 3YN/A
OCF growth 5YN/A